Takeda's $62 billion acquisition of Shire added $31 billion to its debt load. Now, it's looking to cut costs where it can.

A team of scientists clarified the role of the protein LRRK2 in tuberculosis, suspecting that it behaves similarly in Parkinson's.

Early data suggest the new batch of therapies is at least as effective as its predecessor, clearing a potential pitfall on Spark’s path to market.

The strategic partnership tasks Evotec with applying its R&D toolkit to the discovery of solid tumor drugs that Celgene will then pick up and advance.

Sesen Bio presented three-month data showing that its bladder cancer drug Vicinium had a 43% complete response rate.

ImmusanT recently expanded its senior staff, bringing on Daiichi Sankyo’s senior VP for internal medicine, Ken Truitt, as its chief medical officer.

Sanofi is trumpeting new data for a hemophilia A drug developed by Bioverativ that it says could transform treatment of the bleeding disorder.

Galecto Biotech hired Richard Marshall, head of fibrosis discovery at GlaxoSmithKline, to be CMO as it moves into late-phase trials of its IPF drug.